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Available online 31 July 2012The human pentraxin proteins, serum amyloid P component (SAP) and C‐reactive protein
(CRP) are important in routine clinical diagnosis, SAP for systemic amyloidosis and CRP for
monitoring the non‐specific acute phase response. They are also targets for novel therapies
currently in development but their roles in health and disease are controversial. Thus, both for
clinical use and to rigorously elucidate their functions, structurally and functionally intact,
pharmaceutical grade preparations of the natural, authentic proteins are required. We report
here the production from normal human donor plasma and the characterization of the first
such preparations. Importantly, we demonstrate that, contrary to reports using recombinant
proteins and less well characterized preparations, neither CRP nor SAP stimulate the release by
human peripheral blood mononuclear cells in vitro of any TNFα, IL‐6 or IL‐8, nor does SAP
cause release of IL‐1β or IL‐10. Furthermore neither of our preparations was pro‐inflammatory
in mice in vivo.
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Y license. 1. Introduction
The humanpentraxin proteins, serumamyloid P component
(SAP) (Pepys et al., 1997) and C‐reactive protein (CRP) (Pepys
and Hirschfield, 2003), are normal circulating plasma proteins
which are important in routine clinical diagnosis. They are also
targets for novel therapies currently being developed for major
diseases (Pepys et al., 2002, 2006; Kolstoe et al., 2009; Bodin et
al., 2010; Gillmore et al., 2010). However some of their putative
roles in health and disease are controversial. Comprehensively
validated, highly purified, authentic, native, structurally intact
and fully functional human SAP, isolated from normal human
plasma, is essential for SAP scintigraphy (Hawkins et al., 1988b,
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Human CRP of comparable quality and authenticity is also
necessary, for both critical experimental studies in vitro and in
vivo studies in normal human volunteers, to rigorously establish
its functional effects. Material for human use in vivomust be of
pharmaceutical quality, produced under conditions compliant
with current standards of current good manufacturing practice
(cGMP), in order to be acceptable to ethical and regulatory
authorities.We report here the production and characterization
of the first such preparations.
Human SAP is universally present in all amyloid deposits
(Pepys et al., 1997) as a result of its avid calcium dependent
binding to all types of amyloid fibrils (Pepys et al., 1979b),
regardless of their protein composition. We utilized this
property in our invention of radiolabeled SAP scintigraphy for
the safe, non‐invasive diagnosis and monitoring of amyloid
deposits in systemic amyloidosis (Caspi et al., 1987; Hawkins et
al., 1988b, 1990a, 1990b). This method revealed much of the
previously obscure natural history of the different forms of
systemic amyloidosis, including the critical fact that amyloid
deposits can regress when the abundance of the respective
amyloid fibril precursor protein is substantially reduced
(Hawkins et al., 1993a, 1993b; Holmgren et al., 1993; Hawkins,
1994). These observations have underpinnedmajor advances in
diagnosis and management of amyloidosis and led to much
improved patient survival, especially in the UK National Health
Service National Amyloidosis Centre which is directly funded by
the UK Department of Health to provide diagnostic and
management advisory services for the whole UK national
caseload. The Centre follows the largest and most diverse
cohort of systemic amyloidosis patients in the world,
currently sees more than 3000 patients and performs about
1000 SAP scintigraphy examinations annually. The investi-
gation requires intact, native, highly purified, clinical GMP
grade human SAP for labeling with 123I and intravenous
injection into the patient. Unrelated to its use in diagnosis
and monitoring, SAP contributes to the pathogenesis and/or
persistence of amyloid deposition in vivo and is the target of
novel therapeutic approaches to elimination of amyloid
deposits which we have invented and are developing for
clinical testing in collaboration with GlaxoSmithKline
(www.pentraxin.com) (Pepys et al., 2002; Kolstoe et al.,
2009; Bodin et al., 2010; Gillmore et al., 2010).
The physiological functions of neither human SAP nor CRP
are fully understood but the most robust and reproducible
observations indicate that they contribute to innate immunity
against some bacterial infections. We have demonstrated this
for smooth Gram negative bacteria with SAP (Noursadeghi et
al., 2000) and for pneumococci with CRP (Loeffler et al., 2009).
The avid binding of SAP to DNA (Pepys and Butler, 1987) and
chromatin (Butler et al., 1990) strongly suggests that SAP may
play a role in the appropriate, safe handling of these materials
in vivo. More controversially it has been reported that SAP has
an anti‐fibrotic effect, for which several different mechanisms
have been claimed, most recently via stimulation of IL‐10
production (Castaño et al., 2009). There is even more wide
ranging controversy over possible biological roles of human
CRP, which has been claimed to be pro‐inflammatory, cytokine
stimulating, pro‐atherogenic and pro‐thrombotic (Ballou and
Lozanski, 1992; deMaat and Trion, 2004; Labarrere and Zaloga,
2004; Bisoendial et al., 2005, 2007a, 2007b, 2009). Howeverhuman SAP is a constitutive plasma protein with a circulating
concentration in the range of about 20-50 mg/L (Nelson et al.,
1991) which is tightly regulated and almost constant in each
individual. In contrast, human CRP is the classical, highly
dynamic, rapidly responsive, entirely non‐specific acute phase
protein with a 10,000 fold concentration range of about 0.05 to
over 500 mg/L (Shine et al., 1981; Pepys and Hirschfield, 2003).
Neither of these behaviors is consistent with a role in regulation
of cytokine production and there is absolutely no clinical
evidence in humans or experimental evidence in animals that
endogenously produced high human CRP concentrations are
inherently pro‐inflammatory. There are also compelling, well
controlled, rigorous in vitro and in vivo studies which show
no stimulation of cytokine production by the pentraxins
(Hirschfield et al., 2003, 2005; Gillmore et al., 2004; Pepys,
2005; Pepys et al., 2005; Taylor et al., 2005; Taylor and van
den Berg, 2007; Tennent et al., 2008).
Most reports on pro‐inflammatory effects of human CRP
preparations have used inadequately characterized material
isolated from human biological fluids or, more recently,
commercial recombinant CRP produced in E. coli. The latter,
manufactured only by the Oriental Yeast Company of Japan
(Tanaka et al., 2002), is intended for use as an immuno-
chemistry standard, and is sold by many different biochem-
ical reagent companies. It is heavily contaminated with
endotoxin and likely other bacterial products (Pepys et al.,
2005). Although it has been claimed that a single gel filtration
step removed all such contamination from this recombinant
product (Bisoendial et al., 2005), experiments in two indepen-
dent laboratories, using authentic, highly purified, very low
endotoxin content, human CRP did not produce any pro‐
inflammatory effects in vitro or in vivo in mice (Pepys et al.,
2005; Taylor et al., 2005). The reports claiming anti‐fibrotic
activity of SAP are also poorly controlled and/or otherwise
flawed (Pilling et al., 2003; Haudek et al., 2006; Pepys et al.,
2007; Tennent et al., 2007). Their conclusions are not supported
by the complete absence of any abnormalities of connective
tissue or fibrosis in patients on long term treatment with the
SAP‐depleting drug, CPHPC, in whom SAP values are persis-
tently reduced by 90-99% (Gillmore et al., 2010), or in mice
with either deletion of the SAP gene or transgenic expression of
human SAP (Botto et al., 1997; Bickerstaff et al., 1999; Gillmore
et al., 2004). In order to provide suitable reagentswithwhich to
resolve these various controversies we have isolated from the
plasma of healthy individuals, pharmaceutical GMP grade
preparations of human CRP and SAP and fully characterized
them as contaminant‐free and structurally and functionally
intact.
2. Materials and methods
2.1. Plasma collection and testing by the Bio Products Laboratory
Ltd
Plasma, derived exclusively frompaid donors in theUSA,was
collected at centers approved by the UK Department of Health.
Donor selection, donor examination and plasma collection were
performed according to standards and/or requirements set by
the UK Department of Health, in accordance with the European
Pharmacopoeia monograph ‘Human Plasma for Fractionation’.
Every donation was tested and found non‐reactive for: i)
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C virus (HCV); iii) antibodies to human immunodeficiency virus
1 and 2 (HIV); iv) hepatitis A virus, HIV, HBV, HCV and
parvovirus B19 by nucleic acid amplification technique
(NAT) conducted by minipool testing. Units with a parvovi-
rus B19 titer of greater than ~105 IU/mL were excluded to
guarantee that the B19 titer of the starting pool did not
exceed 104 IU/mL. Arrangements for plasma pool testing
complied with the requirements of the CPMP Note for
Guidance on Plasma‐Derived Medicinal Products CPMP/
BWP/269/95. The plasma pool used for the preparation was
derived from thousands of individual donors and was tested
by the Bio Products Laboratory Ltd (BPL) and by the UK
National Institute for Biological Standards and Control
(NIBSC). Tests for HBsAg, anti‐HIV1/2 and anti‐HCV and for
HCV RNA by NAT were negative (non‐reactive) for all tests.
Arrangements for manufacturing complied with the require-
ments of CPMP Note for Guidance on Plasma‐Derived Medic-
inal Products CPMP/BWP/269/95. The standard operating
procedure covering the donations details the actions to be
taken in the case of a known or suspected defect of a donation
and includes notifying any third party supplied with this
material.
2.2. Isolation of SAP and CRP from plasma
The starting pool of plasma, collected by plasmaphoresis
using sodium citrate anticoagulant, was stored at -35 °C, before
conditioning at -10 °C for ~50 h and then thawed at ~0 °C to
+2 °C for collection of the cryoprecipitate by centrifugation.
The supernatant was treated with 0.5% w/w celite (Hyflo
Supercel) before ethanol fractionation based on a modification
of theKistler andNitschmannmethod (Kistler andNitschmann,
1962). Fraction A+1 was precipitated at pH 5.85, 19% v/v
ethanol and -5 °C and collected by centrifugation. This paste
was resuspended in water for injection, the ionic strength
adjusted using sodium phosphate/acetic acid buffers (Kistler
and Nitschmann, 1962) and fraction B+1 was precipitated
at pH 5.1, 17% v/v ethanol and -3 °C and collected by
centrifugation. The B+1 paste contains SAP and CRP at about
500-900 mg/kg and 10-20 mg/kg respectively, reflecting their
respective concentrations in normal human plasma of about
20-40 mg/L and 0.8 mg/L. The pentraxins were isolated from
38 kg of B+1 paste by solubilization in 10 mM Trometamol,
140 mM NaCl, 1 mM EDTA, pH 8.0, fractionation on DEAE
Sephadex and then calcium dependent affinity chromatography
on phosphoethanolamine covalently immobilized on Sepharose,
as previously described (Pontet et al., 1978; de Beer and Pepys,
1982; Hawkins et al., 1991; Carlucci et al., 2010). Briefly, the
extracted B+1 paste was depth filtered on a Millipore CE15
filter before adding 5% v/v of 0.2 M EDTA, pH 7.0 and mixing
437 kg of the solution with 6 kg of dry DEAE Sephadex which
had been swollen in distilled water and then equilibrated with
10 mMTrometamol, 140 mMNaCl, 1 mMEDTA, pH 8.0,making
a wet weight of gel of ~100 kg. After 1 h at room temperature
the DEAE was washed with 10 mM Trometamol, 140 mMNaCl,
1 mM EDTA, pH 8.0, to remove unbound proteins before eluting
the bound proteins with 2 M NaCl. All these steps were
conducted at 8-15 °C. Trometamol (100 mM) and CaCl2
(50 mM) solutions were added to the eluate to yield a final
concentration of 10 mM Trometamol, 5 mM CaCl2 at pH 8.0before sequential filtration at 20 °C through a Pall Preflow UB
filter followed by a Pall Flurodyne II 0.45 μ filter (Pall
Corporation). The filtrate was then subjected to solvent‐
detergent treatment with polysorbate 20 (8.8 g/L) and tri‐n‐
butyl phosphate (2.45 g/L) for 120 min at 22-26 °C. This virus
inactivation procedure was prospectively validated using HIV
and independently audited. The process was also concurrently
validated using three other enveloped viruses: sindbis, bovine
viral diarrhea virus (BVDV) and infectious bovine
rhinotracheitis virus (IBRV). The reductions in virus titers
achieved were >5.3 logs for HIV, >7.0 logs for sindbis, >4.0
logs for BVDV and>6.4 logs for IBRV, providing good assurance
that the solvent‐detergent step would be effective against
HIV1/2 and HCV if they were present. There is no universally
accepted model for HBV, but solvent detergent is also
expected to be very effective against this lipid‐enveloped
virus. The 414 kg eluate from DEAE was then mixed with 7 L
of phosphoethanolamine-Sepharose which was synthesized
using NHS‐activated Sepharose Fast Flow according to the
manufacturer's instructions (GE Healthcare). After 2.5 h at
room temperature to enable the SAP and CRP to bind to the
immobilized phosphoethanolamine, the fluids were re-
moved by filtration and the resin was washed with 10 mM
Trometamol, 140 mM NaCl, 2 mM CaCl2, pH 8.0 until no
further protein eluted. The beads were then poured into a
BPG 200/500 chromatography column (GE Healthcare),
packed with the same wash buffer, and the bound CRP was
eluted with 1 mM phosphocholine in solution in the same
buffer. The eluted CRP was collected, pooled in sterile plastic
bags and stored frozen at ≤-35 °C. SAP bound to the column
was then eluted with 10 mM Tris, 140 mM NaCl, pH 8.0
containing 10 mM EDTA and stored frozen at ≤-35 °C. The
two non‐enveloped viruses which have been associated
with disease transmitted by transfusion of blood and blood
products, hepatitis A and human parvovirus B19, are not
affected by solvent‐detergent procedures. The eluates
containing SAP and CRP from the phosphoethanolamine-
Sepharose columnwere therefore filtered through Pall DV50
50 nm and Pall DV 20 20 nm filters respectively, to reduce
the risk from these viruses. The integrity of the nm filters
was validated after use. At the time of the SAP preparation in
2004-5, 50 nm filtration had been approved for several
product lines but when the CRP was filtered in 2008, 20 nm
filtration, which is more effective against B19, was in more
common usage. The filtered SAP was concentrated and then
buffer exchanged against 10 volumes of 10 mM Trometamol,
140 mM NaCl, pH 8.0 on a Millipore Pellicon device with a
30,000 Da cut off membrane, to remove EDTA and any
remaining traces of polysorbate 20 and tri‐n‐butyl phosphate.
EDTA, 0.2 M pH 7.0, was added to the virus filtered CRP to a
final concentration of 10 mM to chelate calcium and release
bound phosphocholine before concentration and buffer
exchange against 10 volumes of 10 mM Tris, 140 mM NaCl,
pH 8.0 to remove all phosphocholine, EDTA and any remaining
traces of polysorbate 20 and tri‐n‐butyl phosphate. After
harvesting the concentrated CRP, 1 M CaCl2 was added to
provide a final calcium concentration of 2 mM. Finally the
isolated proteins were pre‐filtered at 1.2 μm and then sterile
filtered at 0.22 μm into sterile containers. The suitably aliquoted
preparations were stored, CRP at 3 mg/mL at 4 °C and SAP at
15 mg/mL frozen at -80 °C. All buffers and solutions were made
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conducted under strict pharmaceutical GLP conditions and was
fully compliant with GMP.
2.3. Characterization of the isolated GMP CRP and SAP preparations
The concentrations of salt, buffer salts and residual solvent
detergent materials were assayed by standard methods. Total
protein concentration was determined, in triplicate samples
diluted with their respective solvents to produce absorbance
values of about 0.1 with a 1 cm light path, by measuring net
A280 after subtraction of A320 produced by light scattering. The
precisely measured specific extinction coefficients (1% w/v,
1 cm) of 17.1 for human SAP and 17.5 for human CRP (de Beer
and Pepys, 1982) were used to calculate the respective protein
concentrations. Bacterial endotoxin was assayed by the kinetic
LAL test, strictly according to the European Pharmacopoeia
Monograph for Bacterial Endotoxins 2.6.14, and bacterial
growthwas sought by standard culturemethods. Protein purity
was assessed by SDS 8-18% PAGE (ExcelGel, GE Healthcare)
heavily overloaded with samples run under reducing condi-
tions and stained with Brilliant blue R350. Native protein
integrity, absence of aggregation and dissociation were dem-
onstrated by native, non‐denatured 3-8% gradient PAGE in Tris
acetate (NuPAGE Novex, Invitrogen), and by size exclusion
chromatography of 0.02 mg samples in a volume of 100 μL on a
10×30 cm Superdex 200 column equilibrated and eluted at
0.5 mL/minwith 10 mMTris, 140 mMNaCl, pH 8.0 for SAP and
10 mM Tris, 140 mM NaCl, 2 mM CaCl2, pH 8.0 for CRP.
The integrity of the protomers of SAP and CRP was verified
by electrospray ionization mass spectrometry (ESIMS). After
buffer exchange into pure water 2-4 μL samples were diluted
1/10 with a 50%MeCN/49.9%H2O/0.1%HCOOH v/v/v mixture
and infused into the electrospray source of a Quattro II triple
quadrupole mass spectrometer (Micromass) under the follow-
ing conditions: ES positive ion mode, 2.49 s scan with 0.11 s
interscan delay, mass range m/z700–2750, cone voltage ramp
17–116 V, capillary at 3 kV. The concentrations of the specific
proteins were confirmed by specific immunoassays for human
CRP (Eda et al., 1998; Erlandsen and Randers, 2000) and SAP
(Nelson et al., 1991) respectively. Functional integrity of the
proteins for specific ligand recognition in vitro was established
by their complete, strictly calcium dependent binding to
phosphoethanolamine-Sepharose (Hawkins et al., 1991). The
authentic native state of the SAP preparation and its functional
integrity for localization to amyloid deposits were investigated
in vivo in normal healthy C57BL/6 mice and C57BL/6 mice in
which AA amyloidosis had been induced by repeated injection
of casein (Hawkins et al., 1988a, 1991), in comparison with a
highly purified non‐GMP batch of human SAP. SAP was trace
radiolabeled with 125I as previously described (Hawkins et al.,
1988a, 1991). Unlabeled non‐GMP SAPwas spikedwith labeled
GMP SAP at approximately 0.3 μg (100,000 cpm) per mg.
Normal healthy adult female C57BL/6mice received 1 mgof the
spiked SAP by IV injection and were then bled at intervals
thereafter for assay of total human SAP by electroimmunoassay
and counting to estimate clearance of the labeled GMP human
SAP. Two groups of AA amyloidotic mice received 0.3 μg tracer
doses of either GMP or non‐GMP 125I‐SAP by IV injection. After
24 h theywere bled out, killed and radioactivitywas determined
in the spleen and liver, which contain the amyloid deposits inthis model. Pro‐inflammatory effects of the preparations in vivo
were sought in wild type adult female C57BL/6 mice weighing
~20 g each, which were pre‐bled 48 h before testing to provide
individual baseline values of the sensitive murine acute phase
reactants, SAP (Pepys et al., 1979a) and serum amyloid A protein
(SAA), and then given 720 μg per mouse of each human protein
IV (~30 mg/kg). Controlmice received vehicle alone and allwere
bled out at 24 h for assay of mouse SAP (Pepys, 1979) and SAA
(BioSource UK) in the serum.
2.4. Effects of the GMP SAP and CRP preparations on cytokine
release by human peripheral blood mononuclear cells in vitro
Assay reagents. Aseptic technique was used for antibody
manipulations and for the cell culture procedures. Antibodies
and reagents for cell culture procedures were free from
detectable pyrogen/endotoxin. Culture medium for all exper-
iments was MEM (Gibco 21090) supplemented with 2 mM
L‐glutamine (Sigma G7513), 100 U/mL penicillin and
0.1 mg/mL streptomycin (Sigma P0781), non‐essential amino
acids (Gibco 11140), and 1 mM HEPES (Sigma H0887).
Phosphate buffered saline (PBS) was prepared by dilution of
sterile 10x stock solution (without calcium and magnesium,
Gibco 70011-036) with sterile water (Baxter UKF7114). Di-
lutions of proteins and endotoxin were tested in quadruplicate
with cells from four donors in each assay. Isolation of peripheral
blood mononuclear cells (PBMCs). Human whole blood was
donated by consenting employees of NIBSC in accordance with
local ethical practice. Donors were healthy males and females
aged mid twenties to mid sixties, free of symptomatic viral
and bacterial infections and who had not taken steroid
anti-inflammatory medicines during the previous 7 days or
non‐steroid anti‐inflammatory medicines during the 3 days
prior to giving blood, nor were taking any other drug known
to influence immunological responses. PBMCs and donor
plasma were isolated, within 30 min of venesection, from
heparinized (Fragmin Dalteparin Sodium, Pharmacia, 10 IU/
mL blood) whole blood by density gradient centrifugation
using Histopaque-1077 (Sigma H8889) layered beneath
whole blood diluted 1/2 with PBS. Centrifugation at 340 g
was used to separate PBMCs and plasma at room tempera-
ture and for washing the cells. After washing 2-3 times in
PBS and re‐suspension in culture medium, PBMCs were
stored in a humidified incubator at 37 °C, 5% CO2, and used
within 5 h of venesection. Donor plasma was stored at room
temperature until used, also within 5 h of venesection.
Enzyme linked immunosorbent assay (ELISA) for cytokines.
ELISAs for the measurement of TNFα, IL‐6 and IL‐8 were
carried out as previously described (Findlay et al., 2010).
WHO international standards (IS) produced at NIBSC for
TNFα, IL‐6 and IL‐8 were used as calibrants for the cytokine
ELISAs (preparation 88/786 for TNFα, 89/548 for IL‐6 and
89/520 for IL‐8). The standards, two‐fold dilutions ranging
from 15.6 to 4000 pg/mL, were diluted in cell culture
medium supplemented with 2% v/v plasma. Supplemented
culture medium was used as a blank. For the measurement
of IL‐1β, monoclonal anti‐human IL‐1β capture antibody
(Duoset DY201, R & D Systems) was added in PBS, to wells of
96‐well microtiter plates (Immuno MaxiSorp, NUNC) at
1 μg/mL (100 μL/well). Plates were covered and left for
16-24 h at 4 °C prior to washing 3 times with wash buffer
a b c
1 2 3 4 5 1 2 3 1 2
Fig. 1. SDS 8-18% PAGE of reduced samples of GMP human pentraxins. a, GMP
human SAP. Lane 1, molecular weight marker proteins: 94 kD, 67 kD, 43 kD,
30 kD, 20.1 kD, 14.4 kD; lane 2, SAP 25 μg; lane 3, SAP 50 μg; lane 4, SAP 75 μg;
lane 5, SAP 100 μg. b, GMP human CRP. Lane 1, marker proteins; lane 2, CRP
60 μg; lane 3, CRP 30 μg. The trace higher molecular weight impurities
identified by proteomic analysis as IgM μ chain and plasmin/plasminogen
respectively are seen in lanes 2 and 3. c, GMP human CRP. Lane 1, marker
proteins; lane 2, CRP 5 μg.
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were blocked with 100 μL of 1% w/v bovine serum albumin
(Sigma A7888) in PBS. Cell‐conditioned medium, 50 μL, or
IL‐1β standard (WHO IS 86/680, NIBSC) at 2‐fold dilutions
ranging from 15.6 to 4000 pg/mL (in culture medium
containing 2% v/v plasma or serum as specified below), was
added to each well coated with capture antibody. Concen-
trations of standard and supplemented culture medium
alone were added to every microtiter plate in duplicate.
Biotinylated polyclonal anti‐human IL‐1β detection anti-
body (Duoset DY201, R & D Systems) 50 μL in PBS containing
1% w/v bovine serum albumin was added to wells prior to an
overnight incubation of the covered plates at 4 °C. Plates were
washed 3 times in wash buffer prior to addition of 100 μL
peroxidase‐conjugated streptavidin (Jackson ImmunoResearch
Laboratories) inwashbuffer; plateswere incubated for 15 min at
room temperature and then washed 3 times in wash buffer
and once in demineralized water. O‐phenylenediamine
dihydrochloride substrate solution (Sigma P8787), 100 μL
in citric‐acid monohydrate solution containing 30% v/v
hydrogen peroxide, was added and, 5-10 min later, 50 μL
1 M sulfuric acid. The absorbance values were calculated by
subtracting the OD values measured using a corrective
540 nm filter from the OD values measured with a 450 nm
filter. ELISA of IL‐10 was as for IL‐1β except that IL‐10 Duoset
DY217B (R & D Systems) was used and the IL‐10 standard
was WHO IS 93/772, NIBSC. Cytokine release studies using
human PBMC (monocyte activation test described in the
European Pharmacopoeia 2.6.30) were conducted as de-
scribed previously (Poole et al., 2003; Gaines Das et al.,
2004). Briefly, PBMC were isolated from human heparinized
peripheral blood within 4 h after its collection as described
above. Clinical grade CRP and SAP proteins were incubated
with 0.5–1.0×106 PBMC/mL in 250 μL of supplemented
MEM culture medium containing 2% v/v autologous plasma.
All cultures were in quadruplicate under aseptic conditions,
with sterile, pyrogen free reagents and consumables, at 37 °C,
in 5% CO2 in humidified air for 16–24 h. All responses to CRP
and SAP were compared with simultaneous responses to
bacterial endotoxin (the second WHO international endotoxin
standard, 94/580) in the same assays, including spiking
experiments.
3. Results
3.1. Protein purity
The isolated SAP preparation at 15 mg/mL contained 6 mg/L
residual polysorbate‐20 and b0.2 mg/L of tri‐n‐butyl phosphate.
These compoundswere not assayed in the final CRP preparation,
whichwas at 3 mg/mL, but it hadundergone the sameextensive
buffer exchange, ‘washing’ process, as the SAP. Both protein
preparations were sterile with no bacterial growth on culture.
The bacterial endotoxin content of the SAP was b0.003 EU/mg
and for CRP was b0.1 EU/mg, that is below the detection limit
detection with the CRP at 3 mg/mL. Heavily overloaded
SDS-PAGE of the SAP preparation showed no significant bands
other than SAP itself (Fig. 1a). The very faint bands seen in lanes
loadedwithmore than50 μg of SA comprise less than 0.1% of the
total protein. The CRP preparation contained two very faint
bands on either side of the 94 kD marker, in addition to CRP(Fig. 1b). These other proteins comprised less than 1% of the
total protein and their presence is not surprising because several
chromatographic steps required to remove traces of other
proteins in preparing the most highly purified CRP (de Beer
and Pepys, 1982;Hawkins et al., 1991; Carlucci et al., 2010)were
not possible in the present pharmaceutical GMP procedure. The
trace higher molecular weight proteins were identified by
proteomic analysis, usingmass spectrometry of trypsin digested
fragments of the bands excised from the SDS‐PAGE. The lower
mass band was the μ heavy chain of IgM and the higher mass
band was plasmin/plasminogen (data not shown). The very
faint trace bands ofmass lower than the SAP and CRP protomers
are characteristic cleaved fragments of the protomers which are
derived from intact pentameric pentraxins when they are
reduced and denatured; they are invariably present in
pentraxins isolated from ex vivo human material. No SAP was
detected in the CRP preparation and no CRPwas detected in the
SAP preparation, which were tested at 3.0 and 1.5 mg/mL
respectively using assayswhich in both cases detected the other
pentraxin at 1 μg/mL (Nelson et al., 1991; Shine et al., 1981).3.2. Protein structural integrity
The authentic covalent structures of the protomers of each
pentraxin were confirmed by ESIMS, with average molecular
masses (SD) (n=3) of 25,462.64 (0.39) for SAP and 23,027.46
(0.52) for CRP, corresponding exactly to the predicted masses
for their respective amino acid sequences, plus glycan in the case
of SAP (Pepys et al., 1994) and with N‐terminal PCA in CRP
(Oliveira et al., 1979). Integrity of the authentic native non‐
covalent pentameric assembly of each proteinwas confirmed by
gel filtration chromatography, which also showed the absence of
any aggregation or dissociation into free protomers (Fig. 2). The
same result was obtained with the SAP preparation in non‐
denatured gradient PAGE (Fig. 3). Unlike the 4-30% gradient gels
in Tris glycinewe have previously used (de Beer et al., 1982) but
which are no longer available, human CRP does not form a
discrete band in the present system.
Fig. 2. Size exclusion chromatography of GMP human pentraxins on Superdex 200. Both SAP (left) and CRP (right) gave single sharp peaks corresponding to their
known molecular masses under the conditions used, in which SAP runs as stable decameric assemblies of pairs of the native pentameric structure and CRP runs as
a single native pentamer.
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Functional activity of the proteins was confirmed by their
reproducible, 100%, strictly calcium dependent binding to
phosphoethanolamine-Sepharose beads (not shown). Further-
more these human proteins had the expected plasma clearance
half life of ~3-4 h after intravenous injection into normal wild
type C57BL/6 mice (Baltz et al., 1985; Hawkins et al., 1988a)
(shown for SAP in Fig. 4; not shown for CRP). This is a very
sensitive test for structural and functional integrity of plasma
proteins as even extremely subtle alterations, which may be
undetectable by in vitro biophysical and biochemical methods,
cause accelerated clearance of plasma proteins from the
circulation in vivo. A key functional property of human SAP is
its avid binding to amyloid deposits in vivo (Pepys et al., 1979b,1 2 3
Fig. 3. Native non‐denatured 3-18% gradient PAGE of human SAP. Lane 1,
molecular weight marker proteins: 669 kD, 440 kD, 232 kD, 140 kD; lane 2,
GMP human SAP 13 μg; lane 3, non‐GMP human SAP for comparison 13 μg.
Human SAP is known to run as a stable decamer, mass 254,620, under these
conditions (de Beer et al., 1982).1997) and the clinical objective of the present GMP SAP
preparation was to provide material for routine clinical SAP
scintigraphy in the National Amyloidosis Centre. We therefore
confirmed that trace radiolabeled GMPSAPwas cleared inmice
in vivo at precisely the same rate as a non‐GMP preparation of
human SAP isolated in our laboratory (Fig. 4). Furthermore
both the GMP and the non‐GMP SAP preparations localized to
the same extent in the amyloidotic organs of mice with
systemic AA amyloidosis. On this basis, we proceeded to use
the GMP SAP for clinical scanning in patients with known or
suspected amyloidosis and it has so far been deployed for this
purpose in over 10,000 individuals with excellent results and
no adverse effects whatsoever. Typical images are shown in
Fig. 5.
3.4. Effect of GMP pentraxins on cytokine release in vitro
In four independent experiments (Tables 1, 2, Figs. 6, 7))
each using PBMC from four donors (15 different donors inTime after injection (min)
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Fig. 4. Blood clearance of tracer 125I‐GMP SAP (● ●) and abundant (1 mg/
mouse) unlabeled non‐GMP SAP (■—■) administered simultaneously IV to
adult C57BL/6 mice (n=3). Each point represents the mean (SD) of
measurements in 3 mice. The initial elimination of a larger proportion of
the non‐GMP material probably reflects the presence of aggregated
molecules not present in the GMP product but the subsequent clearance
kinetics are essentially the same for the two preparations confirming that
the labeled GMP SAP behaves like the intact native protein.
2005 2009 2011 
Fig. 5. Posterior whole body images of SAP scintigraphy scans of a patient with systemic monoclonal immunoglobulin type (AL) amyloidosis who presented with
major liver involvement and proteinuria in 2005. He responded well to chemotherapy with substantial regression of amyloid by 2009 when his liver and renal
function had returned to normal. The underlying plasma cell dyscrasia then gradually relapsed during 2009-11 leading to recurrence of proteinuria caused by
reaccumulation of renal amyloid shown in the 2011 scan.
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3), neither CRP (at up to 100 μg/mL with 11 donors in 3
independent experiments), nor SAP (at up to 100 μg/mL with 4Table 1
Effect of GMP human pentraxins on cytokine production/release by human periphe
Experiment Protein Cytokine responses
IL-6 (pg/mL)
1 Medium only control 119±46
CRP (1.0, 10.0, 100 μg/mL) 73±33, 136±28, 36
ET (0.03, 0.06, 0.075 EU/mL) 1123±725, 16207±8
58204±38546
ET spike recovery (%) for
CRP (100 μg/mL)+ET (0.075 EU/mL): 95±11%
2 Medium only control 153±16
CRP (1.0, 10.0, 100 μg/mL) 133±42, 277±109, 8
ET (0.03, 0.06, 0.075 EU/mL) 1369±438, 9595±21
14675±2549
ET spike recovery (%) for
CRP (100 μg/mL)+ET (0.075 EU/mL): 99±11%
3 Medium only control 36±29
CRP (1.0, 10.0, 100 μg/mL) 43±42, 71±48, 56±
ET (0.03, 0.06, 0.075 EU/mL ) 2640±1292, 16695±
22913±8871
ET spike recovery (%) for
CRP (100 μg/mL)+ET (0.075 EU/mL): 86±16%
3 Medium only control 36±29
SAP (0.75, 7.5, 75 μg/mL) 1±1, 5±4, 485±422
ET (0.03, 0.06, 0.075 EU/mL) 2640±1292, 16695±
22913±8871
ET spike recovery (%) for
SAP (75 μg/mL)+ET (0.075 EU/mL): 134±48%
4 Medium only control 96±78
SAP (1.0, 10.0, 100 μg/mL) 24±62, 66±62, 72±
ET (0.03, 0.06, 0.075 EU/mL) 4219±1041, 13698±
25589±8349
ET spike recovery (%) for
SAP (100 μg/mL)+ET (0.075 EU/mL): 90±4%*
Values are mean±SEM; n=4 donors of PBMC except values for 3 donors indicateddonors in one experiment and up to 75 μg/mL with 4 donors in
one other experiment) stimulated release of TNFα, IL‐6, IL‐8, IL‐
1β and IL‐10 above background values; IL‐1β and IL‐10 wereral blood mononuclear cells in vitro.
TNFα (pg/mL) IL-8 (pg/mL)
±21
710,
238±134 20365±15185
1±47 227±103, 256±135,
318±159
13099±17814, 27198±20251,
31778±12719
80, 652±186, 2146±203,
2007±726
56188±30074, 97784±29648,
114944±34071
104±4% 123±29%
37±10 8098±3554
53 23±7, 22±6, 37±12 7190±2900, 7743±3374,
10405±4313
6405, 216±59, 1374±456,
1874±560
62105±22665, 141392±38410,
159508±45048
96±7% 88±12%
37±10 8098±3554
24±16, 22±7, 72±36 7126±3859, 4981±2432,
36270±15847
6405, 216±59, 1374±456,
1874±560
62105±22665, 141392±38410,
159508±45048
140±20% 158±19%
21±10
59 24±9, 24±18, 24±21
10017*, 119±42, 312±170,
498±106
108±15%
with an asterisk (*); ET, endotoxin.
Fig. 6. Absence of cytokine responses to human CRP and SAP. Bars showmean
(SEM) of cytokine release by peripheral blood mononuclear cells from 4
individual donors cultured with endotoxin (ET, EU/mL), CRP or SAP (μg/mL).
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endotoxin stimulated dose‐dependent cytokine release from
the PBMC of all donors (Tables 1, 2). CRP and SAP did not
significantly enhance endotoxin mediated cytokine release,
nor did they interfere in any of the cytokine assays; even at
100 μg/mL of each pentraxin, the assays gave endotoxin spike
recoveries of 86-182% (Tables 1, 2).3.5. Effect of GMP pentraxins on the in vivo acute phase response
in mice
The murine acute phase proteins, SAP and SAA, respond
with exquisite sensitivity to endotoxin and all other toxic and
pro‐inflammatory materials which have been tested (Pepys
et al., 1979a, 2005; Pepys and Baltz, 1983; Poole et al., 1984,
1986). However very high dose, ~30 mg/kg, intravenous
bolus injections of neither GMP SAP nor GMP CRP stimulated
an acute response (Table 3). This is consistent with our
extensive previous experience in mice and rats receiving
even higher doses of highly purified non‐GMP pentraxin
preparations which were free of endotoxin contamination. Itis also consistent with the present finding that neither of the
pentraxin preparations stimulated cytokine release by human
peripheral blood mononuclear cells in vitro.
4. Discussion
The function of a human plasma protein in humans can be
definitively established by studying individuals with genetic
deficiency or abnormality of the protein, by investigating
effects of a specific intervention which persistently depletes
the protein in question, or, possibly, by administering a highly
purified preparation of the intact isolated protein. There is no
rigorous report of any deficiency or even structural poly-
morphism of either human CRP or SAP proteins. Thorough
characterization of preparations of these proteins, whether
isolated from different individuals or from pools of donors, has
so far shown only the single protein sequences corresponding to
their respective single functional genes (Vigushin et al., 1993;
Pepys et al., 1994). The single typical biantennary N‐linked
oligosaccharide of human SAP is also invariant (Pepys et al.,
1994); human CRP is not glycosylated (Vigushin et al., 1993).
Thus no genetic ‘experiment ofNature’ is available for the human
pentraxins. Our drug CPHPC (Pepys et al., 2002) which produces
persistent 90-99% depletion of circulating human SAP for as long
as it is administered, has led to no functional deficit or detectable
adverse effect in 31 adults with systemic amyloidosis treated for
up to 7 years (Gillmore et al., 2010). Any role of humanSAPmust
have been redundant in these individuals and in the 70 or so
other adults subjected to SAP depletion so far, including healthy
normal volunteers (unpublished), patients with Alzheimer's
disease (Kolstoe et al., 2009) and patients with osteoarthritis
(unpublished). No drug is yet available which depletes CRP
although our novel bis‐phosphocholine compounds (Pepys et al.,
2006) are in development for clinical testing (www.pentraxin.
com).
The first GMP grade preparations of isolated human SAP
and CRP which we report here are approved by the UKMHRA
for administration respectively to patients and to human
volunteers. SAP deficiency produces no abnormal phenotype
in unchallenged mice, and since sustained almost complete
SAP depletion in human patients with systemic amyloidosis,
osteoarthritis or Alzheimer's disease has had no adverse
effects, we consider it neither necessary nor ethical to
investigate the effects of large doses of isolated human SAP
in volunteers. Our use of pharmaceutical grade SAP is thus
confined to routine clinical SAP scintigraphy in the National
Amyloidosis Centre, where the dose is 50-100 μg per patient
and over 15,000 studies have been conducted since 1988,
including over 10,000 with the present GMP preparation,
without any adverse effects.
In contrast, infusion of recombinant bacterial CRP, derived
from material which is grossly contaminated with endotoxin
(Pepys et al., 2005) and whichwas purified only by a single gel
chromatography procedure (Bisoendial et al., 2005), elicited a
marked inflammatory reaction in healthy human volunteers
and in patients (Bisoendial et al., 2005, 2007a, 2007b, 2009).
The authors ascribed these effects to human CRP and construed
them as support for a pro‐atherogenic role of CRP. Our studies
with authentic, highly purified human CRP, isolated from
humans rather than from recombinant bacteria, and with very
low endotoxin content, had no pro‐inflammatory effects either
Fig. 7. Absence of cytokine responses to hu man SAP. Bars show mean (SEM) of cytokine release by peripheral blood mononuclear cells from 4 individual donors
cultured with endotoxin (ET, EU/mL) or SAP (μg/mL).
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robust findings seriously questioned the interpretation of
experiments with recombinant bacterial CRP (Pepys et al.,
2005). However we produced the present GMP grade human
CRP from normal human blood donor plasma, processed under
strict pharmaceutical conditions throughout, specifically in
order to rigorously test in humans whether human CRP itself,
rather than any possible contaminants, had pro‐inflammatory
effects in vivo. That study, approved by the UK MHRA, isTable 2
Effect of GMP human SAP on cytokine production/release by human periphera
blood mononuclear cells in vitro.
Experiment Protein Cytokine responses
IL-1β (pg/mL) IL-10 (pg/mL)
4 Medium only control 6±3 24±17
SAP (1.0, 10.0,
100 μg/mL)
24±4, 24±2,
5±5
34±20, 31±
18, 43±26
ET (0.03, 0.06,
0.075 EU/mL)
172±72, 739±
316, 997±335
29±26, 78±
47, 112±41
ET spike recovery (%)
for
SAP (100 μg/mL)+ET
(0.075 EU/mL):
107±13% 182±110%
Values are mean±SEM; n=4 donors of PBMC; ET, endotoxin.
Table 3
Effect of intravenous bolus injection of GMP human pentraxins on circulating
concentrations of murine acute phase proteins.
Injection Mouse SAA mean
(SD) mg/L
Mouse SAP mean
(SD) mg/L
Baseline 24 h post
injection
Baseline 24 h post
injection
Vehicle control
n=5
10 (3) 11 (3) 17 (19) 20 (21)
GMP SAP (~30 mg/kg)
n=5
9 (5) 12 (2) 12 (12) 18 (13)
Vehicle control
n=5
22 (1) 23 (3) 9 (1) 10 (2)
GMP CRP (~30 mg/kg)
n=5
24 (1) 24 (2) 9 (3) 12 (5)lcurrently in progress and will be reported separately. Mean-
while we tested both our GMP SAP and CRP preparations in
vitro on human peripheral blood mononuclear cells and by
injection into mice in vivo to determine whether they
stimulated cytokine production and had pro‐inflammatory
actions.
As shown here, neither protein preparation had any
significant effect either on humanmononuclear cells in culture
in vitro or in mice in vivo. In particular human SAP did not
101M.B. Pepys et al. / Journal of Immunological Methods 384 (2012) 92–102stimulate production of IL‐10 and human CRP did not stimulate
production of the pro‐inflammatory cytokines IL‐1, IL‐6 or
TNFα. The compelling nature of these negative findings is
robustly strengthened by the exhaustive demonstration that
the proteins being tested were both structurally and function-
ally intact and contained no significant detectable contamina-
tion with endotoxin. Comparably rigorous sourcing of starting
material, processing, purification and final product character-
ization of human CRP and SAP preparations are all essential
before different or additional properties can credibly be
assigned to these proteins. Our negative experimental obser-
vations with GMP human CRP are entirely consistent with the
compelling experimental results which show that CRP either
has no effect or may actually be anti‐atherogenic in animal
models (Hirschfield et al., 2005; Kovacs et al., 2007; Tennent et
al., 2008; Koike et al., 2009; Teupser et al., 2011). Finally there is
also now overwhelming clinical epidemiological evidence that
provides no support for a pro‐atherogenic role of human CRP
(Emerging Risk Factors Collaboration et al., 2010; C Reactive
Protein Coronary Heart Disease Genetics Collaboration (CCGC)
et al., 2011).
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